In acute respiratory failure due to severe coronavirus disease 2019 (COVID-19) pneumonia, mechanical ventilation remains challenging and may result in high mortality. The use of noninvasive ventilation (NIV) may delay required invasive ventilation, increase adverse outcomes, and have a potential aerosol risk to caregivers. Data of 30 patients were collected from patient files and analyzed. Twenty-one (70%) patients were weaned successfully after helmet-NIV support (NIV success group), and invasive mechanical ventilation was required in 9 (30%) patients (NIV failure group) of which 8 (26.7%) patients died. In NIV success vs failure patients, the mean baseline PaO/FiO ratio (PFR) (147.2 ± 57.9 vs 156.8 ± 59.0 mm Hg; = 0.683) and PFR before initiation of helmet (132.3 ± 46.9 vs 121.6 ± 32.7 mm Hg; = 0.541) were comparable. The NIV success group demonstrated a progressive improvement in PFR in comparison with the failure group at 2 hours (158.8 ± 56.1 vs 118.7 ± 40.7 mm Hg; = 0.063) and 24 hours (PFR-24) (204.4 ± 94.3 vs 121.3 ± 32.6; = 0.016). As predictor variables, PFR-24 and change (delta) in PFR at 24 hours from baseline or helmet initiation (dPFR-24) were significantly associated with NIV success in univariate analysis but similar significance could not be reflected in multivariate analysis perhaps due to a small sample size of the study. The PFR-24 cutoff of 161 mm Hg and dPFR-24 cutoff of -1.44 mm Hg discriminate NIV success and failure groups with the area under curve (confidence interval) of 0.78 (0.62-0.95); = 0.015 and 0.74 (0.55-0.93); = 0.039, respectively. Helmet interface NIV may be a safe and effective tool for the management of patients with severe COVID-19 pneumonia with acute respiratory failure. More studies are needed to further evaluate the role of helmet NIV especially in patients with initial PFR <150 mm Hg to define PFR/dPFR cutoff at the earliest time point for prediction of helmet-NIV success. Jha OK, Kumar S, Mehra S, Sircar M, Gupta R Helmet NIV in Acute Hypoxemic Respiratory Failure due to COVID-19: Change in PaO/FiO Ratio a Predictor of Success. Indian J Crit Care Med 2021;25(10):1137-1146.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645804 | PMC |
http://dx.doi.org/10.5005/jp-journals-10071-23992 | DOI Listing |
Cureus
December 2024
Pediatric Intensive Care Unit, King Fahad Medical City, Riyadh, SAU.
Background: High-flow nasal cannula (HFNC) therapy has developed as a valuable tool for respiratory support in pediatric critical care. It offers an intermediate level of support between traditional low-flow oxygen and non-invasive ventilation (NIV). Studies suggest its effectiveness in improving oxygen delivery, work of breathing, and secretion clearance.
View Article and Find Full Text PDFPediatr Neonatol
December 2024
Department of Pediatrics, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, 217 Hong Bang Street District 5, Ho Chi Minh City, 700000, Viet Nam; University Medical Center Ho Chi Minh City, 215 Hong Bang Street District 5, Ho Chi Minh City, 700000, Viet Nam; Neonatal Intensive Care Unit, Children's Hospital 2, 14 Ly Tu Trong Street District 1, Ho Chi Minh City, 700000, Viet Nam. Electronic address:
Background: Invasive mechanical ventilation in very-low-birth-weight infants (VLBWI) was associated with immediate and long-term complications. Nasal high-frequency oscillation (nHFO) has recently become a new non-invasive ventilation (NIV) mode for treating respiratory failure in VLBWI. This study aimed to investigate the safety and efficacy of nHFO as an alternative respiratory support to prevent intubation in VLBWI.
View Article and Find Full Text PDFIran J Nurs Midwifery Res
November 2024
Department of Operating Room, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
J Anaesthesiol Clin Pharmacol
April 2024
Anesthesia and Intensive Care, Faculty of Medicine, Aswan University, Aswan, Egypt.
Background And Aims: Even though patient tolerance is critical to the success of noninvasive ventilation (NIV), research on using sedation to improve tolerance to NIV after traumatic chest injuries is limited. We hypothesized that dexmedetomidine would be superior to ketamine in terms of patient tolerance and lengthening the NIV sessions after blunt chest trauma.
Material And Methods: This randomized, double-blinded, placebo-controlled trial included 45 patients of both genders aged 18-60 who needed NIV after blunt chest trauma.
Front Pediatr
December 2024
Soins Intensifs Pédiatriques, Département Femme-Mère-Enfant, Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne, Suisse.
[This corrects the article DOI: 10.3389/fped.2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!